Skip to main content

Fallopian Tube

Fallopian Tube

​Approximate Five Year Survival by Stages

(corrected to exclude death from intercurrent disease)

It should be noted that these figures are approximations of five-year survival data collected from large numbers of patients within a given stage. Extreme caution should be used in attempting to use these data to assign prognosis in an individual case.

Low Risk>95%
Moderate Risk80%
High Risk75%
Extreme Risk20%


1) Classification Criteria (FIGO Staging)

IGrowth limited to the tube
IaGrowth limited to one tube; no ascites
IbGrowth limited to both tubes; no ascites
IcGrowth limited to one or both tubes; ascites present with malignant cells in fluid
IIGrowth involving one or both tubes with pelvic extension
IIaExtension and/or metastasis to the uterus or ovary
IIbExtension to other pelvic tissues
IIIGrowth involving one or both tubes with widespread intraperitoneal metastasis to the abdomen (the omentum, the small intestine and its mesentery)
IVGrowth involving one or both tubes with distant metastasis outside the peritoneal cavity.

2) Staging Diagram

Click image
for larger version


​Revised: March 2000

Adenocarcinoma of the fallopian tube is a rare entity. Its management is the same as for adenocarcinoma of the ovary.

Chemotherapy Protocols

Estrogen Replace​ment Therapy - Site Specific Information

Some gynecologic tumours are considered to be hormone responsive (i.e., some low grade uterine sarcomas). Estrogen replacement in this group of patients should be for symptomatic control. A thorough discussion with the patient of the potential risks and anticipated benefits of such treatment should take place.

Recommendation: continuous estrogen plus progestogen.

Radioth​erapy - General Information


Patients should be reminded that it is their responsibility to keep their recommended follow-up appointments. The objectives of the follow-up visits are as follows: 

  1. To determine the patient's immediate response to the treatment employed    
  2. Early recognition and prompt management of treatment related complications    
  3. Early detection of persistent or recurrent disease    
  4. Collection of meaningful data regarding the efficacy of existing treatment policies and their complications so that any appropriate modifications can be instituted

These objectives are best met by having the initial follow-up examination performed by the Agency medical staff. When appropriate, arrangements will be made for follow-up by the referring physician.

Year 1every 3 months
Year 2every 4 months
Year 3-5every 6 months
Years 5+annually
SOURCE: Fallopian Tube ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2018 Provincial Health Services Authority